Life Sciences Archive » December, 2018

Life Sciences - December, 2018

222 articles

• 5 Most-Read Legal Industry Guests Of 2018
• Top 5 International Tax Cases Of 2018
• 3rd Circ. Questions Legal Standard In Foreign Account Case
• Atty's Widow Asks High Court To Look At Case Against GSK
• CVS Unit's Doubled $1.3M FCRA Deal 'Odd,' Judge Says
• Stericycle Reaches $45M Settlement In Securities Suit
• FDA Tells Stem Cell Cos. Regulatory Eyes Fixed On Them
• Join Suits Over HIV Drugs In Calif., Patients Urge JPML
• Takeda's Patent Infringement Suit Not Antitrust-Proof
• Purdue Says Texas Can't Slip Out From Opioid MDL
• Latham Leads Firms In IPO Deals After Market's Robust Year
• Dental Supply Co. Was In On Price-Fixing, Investors Say
• Pair Overdose Antidote With Opioid Prescriptions, HHS Urges
• 2018 Farm Bill Marks Watershed Moment For Industrial Hemp
• Caribbean Court Sides With Sinovac In Board Dispute
• J&J Can't Shake Miss. AG's Suit Alleging Talc Dangers
• House Tees Off Vote For Revised Tax Bill, But Fate Uncertain
• Ohio Opioid MDL Bellwether Survives Drug Co. Attacks
• J&J Can't Shed $4.7B Talc Verdict In Missouri
• Aralez Ch. 11 Inches Forward With 'Weird' Sale Proposal
• Relators Double Down In Gilead FCA Case After DOJ Threat
• Fresenius Gets Win In Suit Over Hospira Sedative Patents
• Generic-Drug Cos. Want AGs To Shut Up About Price-Fixing
• Judge Finds NY's $600M Opioid Surcharge Unconstitutional
• SF Becomes Latest To Sue Pharma Cos. Over Opioid Crisis
• Cocaine Anesthetic Not FDA-Approved, Rival Drugmaker Says
• UK Looks Harder At Thermo Fisher $925M Microscope Deal
• Talc Miner Released From Fla. Product Liability Suit
• Verrill Dana Adds Health Care, Privacy Expert In Boston
• NJ High Court To Review Merck Shareholder's Doc Request
• 5 Firms Rep GSK, Pfizer In £9.8B Consumer Health Biz Merger
• Ballard Spahr Nabs IP Partner From McCarter & English
• New Hatch-Waxman Integrity Act Brings Hope For Patients
• 3 Firms Guide Bristol-Myers On $1.6B Offer For French Unit
• Questions Follow 9th Circ. Solidification Of Escobar Test
• Ariz. High Court Rejects 9th Circ. Preemption Ruling
• EpiPen MDL Gets Special Master To Deal With Disputed Docs
• DOJ Aims Torpedo At 11 FCA Kickback Suits
• Celgene Wants Mylan Sanctioned For Bid To Add Witnesses
• Where 5 Top MDLs Stand At The End Of 2018
• Sen. Warren Wants HHS To Make, Sell Generic Drugs
• DC Circ. Won't Rehear Med Tech Co.'s $400M Award Denial
• Medtronic, Ex-PTAB Chief Settle Gay Discrimination Suit
• Proskauer Steers $184M RiverVest Life Science-Focused Fund
• $2.4M Settlement Reached In J&J 'Natural' Baby Wash Suit
• The State Of Pharma Class Certification After Asacol
• The Moments That Mattered Most For Legal Ethics In 2018
• How Product Liability Law Works In Denmark
• Both Sides In Insys Case Violated Media Rules, Judge Says
• Insights On Right To Try Act And 'Expanded Access' Concerns
• The Year #MeToo Rocked In-House Law Departments
• Sens. Appear Keen On Drafting New Patent Eligibility Law
• Quest Can't Ditch TCPA Suit Over Debt Collection Call
• CMS Gets Backlash For Drug Prices In TV Ads Proposal
• Deals Rumor Mill: Taisho, Carlyle, Trilantic
• Unilever Wins Suit Over Safety Of St. Ives Face Scrub
• Judge Defends Decision Keeping Talc Cancer Case In Philly
• The Verdicts That Left A Mark In 2018
• Anthem Nabs Fees To Sanction Insys In $19M Fentanyl Fight
• Records In OxyContin Suit Are Public, Ky. Appeals Court Says
• Merck Tells High Court FDA OK In Rejecting Fosamax Warning
• Coming Soon: FDA Over-The-Counter Drug Approval Overhaul
• Judging A Book: Mills Reviews 'Mississippi's Federal Courts'
• The NantKwest Saga: Do Gov't Expenses Include Attys' Fees?
• MVP: Sullivan & Cromwell's Matt Hurd
• $50M Released Early For 2nd-Priority Dow Implant Victims
• Feds Fight To Keep Insys Grand Jury Instructions Secret
• EpiPen MDL Attys Scolded For 'Mindless Bickering'
• Covington & Burling Steers Merck's €2B Animal Tech Biz Buy
• AstraZeneca Sues Again Over Breast Cancer Drug Patents
• Abbott Labs Wants Atty DQ'd In Worker's Gender Bias Case
• Texas Justices Won't Hear Ranbaxy's Patent Arbitration Row
• 11th Circ. Affirms Scientists' $10.5M Fraud Convictions
• Fed. Circ. Rejects Atty Fee Bid In Surgical Tool IP Suit
• Sanofi Fires Back Against Mylan In Its Bid To Exit EpiPen MDL
• Fed. Circ. Reins In Reach Of Double-Patenting Doctrine
• The 6 Biggest Law Firm Mergers Of 2018
• Judge Fed Up With 'Whiny' Letters In Least Favorite Case
• MVP: Kirkland's Jay Lefkowitz
• The Subtle Art Of Fred Fielding
• Biotech Co. On Hook For $3.6M Int'l Arb. Judgment, Court Told
• MiMedx Dodges Rival's $6.8M Trade Secret, Breach Suit
• Biotech Biz Zymergen Lands $400M Series C Funding
• UT Can't Be Forced Into Patent Case, Ending Cancer IP Row
• PTAB Axes 2 Patents On Insulin Drug Lantus
• Hatch Introduces Bill To Restrict Generics' PTAB Challenges
• 6 Things That Rocked The Legal Industry In 2018
• Merck Loses Zoning Challenge Against Jersey Township
• Direct Buyers Win Cert. In Lamictal Antitrust Suit
• FDA Nixes Proposed Rule On Generic-Drug Warning Labels
• Top Product Liability Cases Of 2018
• MVP: Hogan Lovells' Adam Golden
• Insys Slams BCBS Privilege Claim In $19M Fentanyl Suit
• 5 Of 6 NECC Defendants Guilty In Latest Trial
• How Life Sciences Cos. Can Prepare For Legal And PR Crises
• Protecting Innovation While Justices Ponder Helsinn V. Teva
• FDA Explains Expectations For Drugmakers' Data Retention
• 8th Circ. Won't Revive Express Scripts Breach, Antitrust Suit
• Boston Scientific Wins $35M Verdict In Heart Valve Patent Suit
• IMMC Trustee Wants 3rd Circ. Redo In Ch. 11 Transfer Fight
• FDA Boss Vows Crackdown On Stem Cell, Supplement Cos.
• 1-800 Contacts Asks FTC To Stay Ruling Axing Ad Compacts
• Fed. Circ. OKs Teva's Patent Win Over Allergan Colitis Drug
• EU Court Slashes €100M From Servier Pay-For-Delay Fine
• Synergy Pharma Files Ch. 11, Bausch Health Offers $200M Bid
• 'Bundle' Buys Don't Avert FCA Liability, Feds Say In Bayer Suit
• Ex-Biotech Exec Avoids Prison For Lying To SEC
• MVP: Greenberg Traurig's Lori Cohen
• 10 Tips For Law Firms To Drive Revenue Via Sports Tickets
• Inside Key ABA Guidance On Attorneys' Cybersecurity Duties
• Revising FDA 510(k) Poses Challenges For Device Makers
• Amgen's Biosimilar IP Win Was Wrong, Hospira Tells Fed. Circ.
• Fed. Circ. OKs Stryker's $254M IP Win After High Court Trip
• Dental Products Maker Expands IP War Against Rival At ITC
• Full Fed. Circ. Urged To Review Venue In Cialis Patent Fight
• Accountant Seeks No Prison Time For $18M Tax Return Fraud
• ImmunoCellular Investors Seek OK Of $1.1M Stock Hype Deal
• Hoffman La-Roche Can't Keep Malaria Drug Suit In Fed. Court
• GNC Investors Can't Revive Securities Suit In 3rd Circ.
• Fed. Circ. Provides Clarity On Patent Term Questions
• 3rd Circ. Questions 'Imminent' Shire Antitrust Actions
• Endo Must Face Stock-Drop Claims In Opioid Safety Suit
• Texas Medical Device Co., Atty End Suit Over Alleged Scam
• Opening Comments: A Key Strategic Decision In Mediation
• MVP: Fish & Richardson's Jonathan Singer
• Shire Must Cough Up Some Docs In Pay-For-Delay Suit
• Judge Mulls Several Outcomes For NY Opioid Surcharge Law
• SEC Slams Man's 'Unfocused' Bid To Nix $11.5M Fraud Suit
• Fed. Circ. Upholds PTAB's Axing Of Inventory Tech Patent
• Keryx Investor Sues In Chancery For Akebia Merger Records
• FDA Hit With Suit Over Reporting Leeway For Clinical Trials
• J&J To Face Bulk Of Buyers' Claims In Remicade Antitrust Suit
• Olympus Pleads Guilty, Fined $85M In Tainted Scope Suits
• Medical Device Exec Beats Charges Of Tipping Orioles Player
• BioChemics Receiver Taps Sunstein, Nields For IP Work
• Tardy Claim Dooms $100M Biotech IP Suit In Chancery
• Pharmas Say FTC Pushing Subpoena Limits In AndroGel Row
• Stradling Nabs Ex-Sheppard Mullin M&A Partner
• Proposed FDA Drug Software Rules Strict On Pharma Cos.
• Post-Teva Expert Disclosure Trends In 2 Patent-Rich Districts
• More State Issues The Blue Wave May Shape In 2019
• Why The High Court Will Hear Cochise Consultancy V. US
• 2 Firms Nab Lead In 'Channel-Stuffing' Derivative Suits
• Fed. Circ. Revives Medical Device Co. Laerdal's ITC Case
• Fed. Circ. Reverses Ax Of Novartis Patent Due To 1995 Law
• J&J Can't Escape Retailers' Antitrust Suit Over Remicade
• Impax Says Investors' Drug Price-Fixing Suit Still Fails
• Genentech Asks Del. Chancery To Toss Takeda Patent Fight
• Fed. Circ. Upholds Patent On Novartis MS Drug
• Merck, Glenmark Can't Shake Zetia Pay-For-Delay MDL
• Medical Device Co. Can't Duck Philly Mass Tort Jurisdiction
• Health Hires: Hooper Lundy, King & Spalding, Williams Mullen
• Synergy Pharma Looks To Ditch Suit Over Side Effects, Loan
• Cook Medical Slashes 3rd Bellwether Suit In Vein Filter MDL
• Data-Driven Lawyer: Morgan Lewis' J. Kyle Poe
• Moderna Leads IPO Pair Raising $735M
• A Firsthand Account Of The Helsinn V. Teva Arguments
• Del. Justices Uphold Fresenius' $4.3B Akorn Merger Drop
• Trump Picks Kirkland's William Barr For AG
• JPMorgan, IV Debate The Meaning Of 'And' At Fed. Circ.
• Sherman Act Cut From Clot Drug Suit, State Claims Survive
• Genocea Beats Investor Claims It Hid Truth About Herpes Drug
• Dallas Paper Asks State Justices To Toss Defamation Claim
• Feds Blocked Again From Deposing Israelis In $163M Tax Row
• Mass. Priest Can't Escape SEC's Short-Selling Suit
• Gov't Presses Judge To Force Insys Founder To Produce Docs
• Amgen Settles 12th Sensipar Patent Fight
• Fed. Circ. Questions Allergan On Water's Role In Colitis Patent
• 'Opioid Babies' Denied MDL Separate From Ohio Gov't Suits
• Fed. Circ. Asks Whether Endo's Opioid Patent Was Obvious
• Actelion To Pay $360M To Resolve Copay Kickback Claims
• Data-Driven Lawyer: Ogletree's Evan Moses
• It's Harder To Withdraw From MDLs — For Good Reason
• Sens. Set Meeting To Talk Revamp Of Patent Eligibility Law
• Shire, Takeda Shareholders Give All Clear To £46B Deal
• Texas Says Opioid MDL Won't Let It Stop Deceptive Marketing
• Consumer Class Certified In Contact Lens Price-Fix Row
• Doctors Without Borders Seeks To Undo Gilead Hep C Patent
• Fresenius Hits Akorn 'Disaster' In $4B Del. Merger Appeal
• Kirkland Taps Allen & Overy Atty To Lead New IP Group In UK
• Medtronic To Pay Over $50M To Settle Medical Device Claims
• Data-Driven Lawyer: Kilpatrick Townsend's Kate Gaudry
• Drug Design Defect Litigation Faces Its Demise
• Aralez Ch. 11 Sale Problems Put Case On Path To Mediation
• Tax Court Judge Presses IRS On Mylan Legal Fee Deduction
• Justices Ask Tough Questions In AIA On-Sale Bar Case
• FTC Supports FDA's Plan To Curb Sham Petitioning
• 5 Key Questions As DOJ Torpedoes Gilead FCA Suit
• J&J Tells Fed. Circ. Judge Was Wrong To Nix Zytiga Patent
• Tribes Can't Seek Info On Fed Contracts, IHS In Opioid MDL
• Fed. Circ. Questions How Aventis Cancer Drug Is Inventive
• FDA Issues Proposed Rule For Novel Medical Devices
• 11th Circ. Revives Suit Over Protein Powder Labels
• Pa. Panel Questions Latest Bid To Ax Out-Of-State Mesh Suits
• Fed. Circ. Reluctant To Void CBM Review Of Inventory Patent
• Deals Rumor Mill: Daimler, Ardian, Grail
• Data-Driven Lawyer: Littler's Scott Forman
• Shook Hardy Kicked Off Monster Energy False-Ad Suit
• Property And Casualty Insurers Face A Genomics Revolution
• Antitrust Risk In Agreements Restricting Online Advertising
• Calif. Jury Clears Alere In Bio Test Cup Patent Suit
• Trump Admin. Urges Broad Easing Of Health Laws
• Atty Fighting Sanctions Says Lies Ignored In Insys Case
• Investor Flags Antibiotics Co. Melinta's $75M Stock Sale
• Aralez, Proposed Buyer Pan Creditors' Ch. 11 Sale Challenge
• Fla. Judge Recommends Trimming Pharmacy FCA Suit
• 2 Firms Lead Nov. IPO Action Fueled By Blank Check Cos.
• Novan Can Duck Claims It Misled Investors, Magistrate Says
• Former Walmart Pharmacist Says Race Played Role In Firing
• AIA On-Sale Bar At The High Court: What You Need To Know
• Walmart, 3 Pharma Cos. Sued Over Tainted Combo Drug
• EpiPen Maker Slams Sanofi's Bid To Exit Antitrust MDL
• Fed. Circ. Wary Of Zimmer Call To Cut Stryker Patent Award
• Pharma Co. Egalet's Ch. 11 Statement OK'd In Del.
• A Chance For High Court To Clarify On-Sale Bar
• Judging A Book: Ginsburg Reviews 'The Curse Of Bigness'
• High Court OKs SG To Argue In Merck's Fosamax Appeal
• J&J Led By Profits To Push Allegedly Faulty Mesh, Jury Told
• 5 Things You Should Know About New Rule 23 Amendments
• Data-Driven Lawyer: DLA Piper's Eric Falkenberry
• 7 Firms Steer GSK's £3B India Unit Sale, $5B Oncology Buy
• The Data-Driven Lawyers Of 2018